4//SEC Filing
Margolis Jeff Eliot 4
Accession 0001493152-20-013378
CIK 0000849636other
Filed
Jul 14, 8:00 PM ET
Accepted
Jul 15, 6:13 PM ET
Size
21.8 KB
Accession
0001493152-20-013378
Insider Transaction Report
Form 4
Margolis Jeff Eliot
DirectorVice President, Sec. & Treas.Other
Transactions
- Gift
Series H Preferred Stock
2020-07-13−25→ 0 totalExercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (3,906,250 underlying) - Gift
Series H Preferred Stock
2020-07-13+25→ 25 total(indirect: By Trust)Exercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (3,906,250 underlying) - Gift
Series H Preferred Stock
2020-07-13+450→ 450 total(indirect: By Trust)Exercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (70,312,500 underlying) - Gift
Series H Preferred Stock
2020-07-13−25→ 25 totalExercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (3,906,250 underlying) - Other
Series H Preferred Stock
2020-07-13+500→ 500 totalExercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (78,125,000 underlying) - Gift
Series H Preferred Stock
2020-07-13−450→ 50 totalExercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (70,312,500 underlying) - Gift
Series H Preferred Stock
2020-07-13+25→ 25 total(indirect: By Trust)Exercise: $0.01From: 2020-07-13Exp: 2023-09-30→ Conversion Units (3,906,250 underlying)
Footnotes (7)
- [F1]The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock."
- [F2]On July 13, 2020, Mr. Margolis agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $500,000. On July 13, 2020, the Company issued to Mr. Margolis 500 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock in exchange for the forgiveness of $500,000 of accrued and unpaid compensation, which equates to a per share value of $1,000.00 per share.
- [F3]Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023).
- [F4]These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis' spouse and children, as specified.
- [F5]Mr. Margolis gifted these securities into a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F6]Mr. Margolis gifted these securities into a family trust for the benefit of his son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- [F7]Mr. Margolis gifted these securities into a family trust for the benefit of his daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
Documents
Issuer
RespireRx Pharmaceuticals Inc.
CIK 0000849636
Entity typeother
Related Parties
1- filerCIK 0001573202
Filing Metadata
- Form type
- 4
- Filed
- Jul 14, 8:00 PM ET
- Accepted
- Jul 15, 6:13 PM ET
- Size
- 21.8 KB